Immunome has dosed the first patient in its Phase 1 trial of IM-1021, a novel ROR1-targeted antibody-drug conjugate designed to treat advanced B-cell lymphomas and solid tumors.
Immunome anticipates topline data from the Phase 3 RINGSIDE trial of varegacestat for desmoid tumors in the second half of 2025, marking a key milestone.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.